Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$61.03 - $69.57 $314,060 - $358,007
-5,146 Reduced 57.23%
3,846 $260,000
Q4 2023

Feb 14, 2024

BUY
$61.89 - $69.28 $5,631 - $6,304
91 Added 1.02%
8,992 $605,000
Q3 2023

Nov 13, 2023

BUY
$64.85 - $71.7 $31,646 - $34,989
488 Added 5.8%
8,901 $602,000
Q2 2023

Aug 11, 2023

SELL
$69.91 - $75.81 $38,730 - $41,998
-554 Reduced 6.18%
8,413 $602,000
Q1 2023

May 11, 2023

SELL
$63.15 - $71.6 $148,718 - $168,618
-2,355 Reduced 20.8%
8,967 $622,000
Q4 2022

Feb 14, 2023

SELL
$54.21 - $70.44 $64,347 - $83,612
-1,187 Reduced 9.49%
11,322 $767,000
Q3 2022

Nov 14, 2022

BUY
$53.02 - $135.75 $30,645 - $78,463
578 Added 4.84%
12,509 $686,000
Q2 2022

Aug 01, 2022

BUY
$59.26 - $71.14 $176,061 - $211,356
2,971 Added 33.16%
11,931 $788,000
Q1 2022

May 06, 2022

BUY
$55.72 - $67.12 $38,279 - $46,111
687 Added 8.3%
8,960 $594,000
Q4 2021

Jan 26, 2022

BUY
$54.02 - $63.83 $147,366 - $174,128
2,728 Added 49.2%
8,273 $482,000
Q3 2021

Oct 20, 2021

BUY
$55.56 - $60.79 $42,225 - $46,200
760 Added 15.88%
5,545 $333,000
Q1 2021

May 12, 2021

SELL
$47.16 - $54.44 $1,980 - $2,286
-42 Reduced 0.87%
4,785 $238,000
Q4 2020

Feb 11, 2021

SELL
$48.52 - $58.02 $33,284 - $39,801
-686 Reduced 12.44%
4,827 $241,000
Q2 2020

Aug 05, 2020

SELL
$43.1 - $55.31 $3,103 - $3,982
-72 Reduced 1.29%
5,513 $292,000
Q1 2020

May 11, 2020

SELL
$37.79 - $51.33 $15,607 - $21,199
-413 Reduced 6.89%
5,585 $250,000
Q4 2019

Feb 13, 2020

SELL
$42.46 - $50.46 $1,698 - $2,018
-40 Reduced 0.66%
5,998 $299,000
Q2 2019

Aug 13, 2019

BUY
$37.28 - $41.68 $6,374 - $7,127
171 Added 2.91%
6,038 $249,000
Q1 2019

May 15, 2019

BUY
$35.49 - $43.02 $208,219 - $252,398
5,867 New
5,867 $237,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Rmb Capital Management, LLC Portfolio

Follow Rmb Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rmb Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rmb Capital Management, LLC with notifications on news.